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 Cholecystokinin (CCK) is an important neuroendocrine peptide in the 
gastrointestinal tract, being the major stimulant for exocrine pancreatic secretion and gall 
bladder contraction. As such, cholecystokinin release may be altered in many 
gastrointestinal diseases. Assays for the measurement of cholecystokinin in humans have 
previously been developed and validated. However, to our knowledge, no assay for the 
measurement of CCK in dogs has been analytically validated.  Thus, the objectives of 
this study were to adapt a radioimmunoassay used for the measurement of plasma CCK 
in humans for use in dogs, perform the assay without human reagents, and to analytically 
validate this modified immunoassay for use with canine serum. 
 A human cholecystokinin radioimmunoassay protocol and antiserum were 
generously provided to us by the laboratory of Jens Rehfeld, Copenhagen, Denmark. 
Assay runs were set up to replace all human reagents that are part of the original 
protocol, followed by analytical validation of the adapted assay using canine serum 
samples by determination of sensitivity, dilutional parallelism, spiking recovery, intra-
assay variability, and inter-assay variability. A reference interval for cholecystokinin in 
canine serum was established using 90 serum samples from clinically healthy, fasted 
dogs (12 hrs), using the bottom 97.5th percentile. 
 The sensitivity of the assay was calculated to be 0.5 pmol/L. The lower limit of 
the working range of the assay was taken as the sensitivity at 0.5 pmol/L. For dilutional 
parallelism, observed-to-expected ratios ranged from 101.9 % to 253.6 % for 3 different 
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canine serum samples at dilutions of 1 in 2, 1 in 4, and, 1 in 8. For spiking recovery, 
observed to expected ratios ranged from 96.1 % to 68.2 % for 3 different canine serum 
samples at 4 different spiking concentrations. Coefficients of variation for intra-assay 
variability for 4 pooled serum samples were 3.8, 13.5, 7.9, and 3.9 %. Coefficients of 
variation for inter-assay variability of 4 pooled serum samples were 12.3, 11.6, 7.4, and 
6.4 %. The reference interval for serum CCK concentration was established as 0.0 to 2.8 
pmol/L. 
 All objectives outlined above were successfully met, analytically validating a 
radioimmunoassay for the measurement of cholecystokinin in canine serum. The 
radioimmunoassay for CCK described here is sufficiently accurate, precise, and 
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 In 1928, Ivy and Oldberg observed that canine intestinal extracts stimulated 
gallbladder contractions when infused into other dogs, and proposed the name 
cholecystokinin (CCK) for the causative agent.1,2 In 1943, Harper and Raper found that 
similar intestinal extracts could also stimulate pancreatic enzyme secretion in cats, and 
proposed the name pancreozymin for the causative substance.1 In 1971, Mutt and Jorpes 
purified the active substance in both of the intestinal extracts and determined their amino 
acid sequences. It was discovered then that CCK and pancreozymin were the same 
hormone, and the hormone is now exclusively referred to as cholecystokinin, regardless 
of the stimulatory function.1,3 As such, CCK was among the first gastrointestinal 
hormones to be discovered.4 
 Although CCK is known to play a major role in the central nervous system 
(CNS), its vastly complex and diffuse effects in the CNS are unrelated to its function in 
the gastrointestinal tract.2,3 The effects of CCK outside the gastrointestinal system are 
beyond the scope of this thesis.  
In all species studied thus far, there is a single gene that encodes CCK.1 In 
humans, the CCK gene is located on chromosome 3 in the 3q12-3pter region.1,5 Mature 
CCK mRNA is about 750 bases long, exists in the brain and intestine in almost 
equivalent amounts, and it is most abundant in the cerebral cortex and the duodenum.1 
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Intestinal expression of CCK mRNA is modified by diet with levels declining in fasting 
animals and increasing after feeding.1 CCK is synthesized from large peptide precursors 
and posttranslationally modified through sulfation of the seventh tyrosine residue of the 
COOH-terminus and amidation of the COOH-terminus.3 Somatostatin has been shown 
to inhibit CCK gene expression, and exogenous bombesin can stimulate CCK secretion 
without affecting CCK gene expression.1   
CCK exists in the body in many different forms; this is due to the peptide having 
a varying number of amino acid residues. CCK isoforms described include CCK 58, 
CCK 39, CCK 33, CCK 22, CCK 18, CCK 12, CCK8, CCK 7, CCK 5, and CCK 4.1,6 
The multiple forms of CCK are the result of differential processing by proteolytic 
enzymes of the main 115 amino acid precursor, preprocholecystokinin, which contains a 
single copy of cholecystokinin.6 All of these N-terminally extended forms of CCK have 
in common an α-amidated carboxy-terminal end and require a sulfated tyrosine residue 
for full physiological activity.1,6  
Sulfation is unusual for hormones, but in the case of CCK it is critical for 
biological potency.1 In the pancreas and gallbladder, the unsulfated form of CCK is 
about 1,000-fold less active than the sulfated form.1 CCK 8 is the major form of CCK 
found in the brain, and is the most biologically potent form of CCK that has been 
isolated.1,5 In the intestine, brain, and blood of many species, the larger forms of CCK 
(CCK 33 and 58) are predominant, but are still less potent on a molar basis than CCK 8, 
and are less reactive with CCK antibodies.1,5 It is thought that intracellular processing of 
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CCK occurs to produce the smaller, more biologically potent forms of CCK that are 
secreted into the blood.1 
Gastrin, which has a similar structure to CCK, shares 5 carboxyl-terminal amino 
acids with CCK (Gly-Trp-Asp-Met-Phe-NH2).1,5 As such, gastrin and CCK can interact 
with the receptors of each other and illicit vague responses.1 Moreover, the close 
molecular similarity to gastrin has hampered earlier attempts to measure CCK 
concentrations by use of immunoassays, as almost all antiserum raised against CCK also 
cross-reacted with gastrin.1 In order to bind specifically to CCK receptors, the CCK 
peptide must be extended to 7 amino acids.1 Another problem that has hampered 
accurate quantification of CCK in serum is the fact that the average blood concentration 
of circulating gastrin is 10-100 times greater than that of CCK.1 
CCK is able to exert its biological effects by binding to specific receptors on 
target cells. There are two forms of CCK receptors, the CCK-A receptor and the CCK-B 
receptor. In dogs, CCK-A receptors are found in the stomach and exocrine pancreas, and 
bind sulfated CCK approximately 1,000-fold more efficiently than unsulfated CCK or 
gastrin.1,3 CCK-B receptors in dogs are found in the stomach, exocrine pancreas, 
endocrine pancreas, and brain, and bind both CCK and gastrin with equal affinity.1 
Recent cloning and expression of CCK receptor cDNAs has determined that the gastrin 
receptor in the brain and stomach and are identical to the CCK-B receptor in the brain.1 
Structurally, CCK receptors are composed of a seven transmembrane protein typical of a 
G-protein coupled receptor, and consist of 444 amino acids.1 CCK binds to both 
receptors with three different affinities: very low, low, and high.3 The dissociation 
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constant (Kd) values for the binding of CCK to the CCK-A receptor are: 10 µM (very 
low), 50-200 nM (low), and 50-300 pM (high).3 The Kd values for the binding of CCK to 
the CCK-B receptor are: 10 µM (very low), 2-5 nM (low), and 100-300 pM (high).3  
CCK receptors are activated through several pathways. Both CCK receptors 
activate phospholipase C (PLC), which causes the mobilization of intracellular calcium 
and the activation of protein kinase C (PKC), the mitogen-activated kinase (MAPK) 
cascade, and phosphatidylinositol 3 kinase (PI3K) pathway, causing the CCK-A receptor 
to increase pancreatic secretion and the CCK-B receptor to activate cell proliferation.3  
The CCK-A receptor also activates adenyl cyclase (AC), causing increased cyclic AMP 
concentration (cAMP), and the nitric oxide (NO)/cGMP pathway, causing cell 
proliferation and pancreatic secretion.3 The CCK-B receptor is also responsible for 
mediating growth effects via activation of the JAK2/STAT3 pathway.3  
CCK in the gastrointestinal tract is produced by endocrine cells of the intestinal 
mucosa.1 A cell density gradient exists in the intestine, resulting in a greater number of 
CCK-producing cells in the proximal small intestine, and less CCK-producing cells in 
the distal small intestine.1 Secretory granules containing CCK are concentrated around 
the basolateral surface of the cell.1 Due to this orientation, food and other factors are 
allowed to interact with the apical surface of the cell, with the resulting signal cascade 
eventually leading to the release of CCK from the surface of the cell into the 
bloodstream.1 Outside the gastrointestinal tract, CCK is synthesized in the pituitary 
gland and adrenal medulla of the central nervous system.1 Although distributed in 
neurons throughout the brain, CCK is found in its highest concentrations in the cerebral 
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cortex; the only neuropeptide that is more predominant in the brain than CCK is 
neuropeptide Y (NPY).1,5 
The exact mechanisms by which food causes CCK release in the gastrointestinal 
tract is still largely unknown, but food directly interacting with the exposed apical 
surface of the I cells (CCK cell) in the intestine as well as endogenously produced 
releasing factors secreted into the intestine are both thought to play a role.1 The exact 
mechanisms regulating the production and secretion of CCK in the gastrointestinal 
system are also largely unknown, although evidence suggests that negative feedback is 
of great importance in the regulation of CCK secretion.1  
 The biological effect of CCK in the gastrointestinal tract, after being secreted 
locally or into the bloodstream, is to cause exocrine pancreatic secretion, pyloric 
contraction, gallbladder contraction, delay gastric emptying, and regulate satiety.1,2 In 
the lower esophageal sphincter, sphincter of Oddi, and other sphincter regions, CCK 
produces relaxation as a result of its ability to stimulate nonadrenergic inhibitory 
neurons.6 In regions like the gall bladder and small intestine, CCK produces a neurally 
mediated contraction due to its ability to release the contractile neurotransmitter 
acetylcholine.6 CCK also acts on receptors in the stomach and various nerves to delay 
gastric emptying and regulate satiety.1 Overall, CCK is responsible for coordinating 







The technology of radioimmunoassays (RIA) was first developed by Yalow and 
Berson in the 1950s.7 The development of a RIA for the measurement of insulin earned 
Dr. Yalow a Nobel Prize in Medicine in 1977.8 This RIA for insulin allowed, for the first 
time, the accurate measurement of the concentration of peptide hormones in plasma.7 It 
was the unmatched sensitivity and specificity of the RIA that allowed hormones that 
physiologically are present in only very low concentrations in the blood to be studied. 
By the 1970s, the methodology of the RIA had spread to other medical fields, including 
pharmacology, toxicology, infectious diseases, oncology, and hematology.7  
An RIA is, in essence, a sensitive in vitro assay technique used to measure 
concentrations of antigens. An antigen can be defined as any substance that binds to an 
antibody. A hormone is an example of a frequently measured antigen. To perform an 
RIA, a known quantity of the antigen that is to be measured is linked to a radioactive 
molecule, for instance, by iodination with I125. A known amount of the radiolabeled 
antigen is then mixed with a known concentration of antibody directed against said 
antigen. A plasma or serum sample containing an unknown amount of the same antigen 
is then added to the mixture. This results in competitive antibody binding between the 
radiolabeled antigen and the sample antigen, since the antigens compete for the same 
antibody binding sites. This mixture is allowed to incubate for varying amounts of time 
and at various temperatures. Then a separation solution is added to separate bound 
antigen-antibody complexes, and unbound antigen and antibody and the radioactivity of 
the antigen-antibody complexes is measured using a gammacounter.  
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In general, the greater the concentration of sample antigen, the less radiolabeled 
antigen is bound, and thus a lower count of radioactivity is measured. If the sample 
antigen concentration is low, the opposite is true; a greater amount of radioactivity will 
be measured. Using a set of known antigen standards, a binding curve is generated and 
the concentration of the unknown antigen is estimated based on its binding in relation to 
this curve. RIAs have many advantages, such as their generally low cost, consistency of 
results, and simplicity. 
Early attempts at developing an RIA for the measurement of CCK were met with 
great difficulty. This was due to a variety of factors: conventional isotope labeling 
techniques involved oxidation, which had deleterious effects on the structure and thus 
biological function of CCK, there was a shortage of peptides for immunization, and the 
COOH-terminal sequence of CCK is shared with gastrin, and is strongly immunogenic, 
making antisera raised against CCK non-specific.9,10 Typical isotopic labeling 
techniques led to oxidation of the two methionyl residues on CCK 8; this was overcome 
using nonoxidative labeling as previously mentioned.9 Currently, peptides are no longer 
in short supply; sulfated CCK 8 and iodinated sulfated CCK 8 are commercially 
available for use as standard and tracer, respectively. 
Radioimmunoassays were first described in the 1950s, but it was not until 1977 
that the first reliable CCK RIA was developed by Jens Rehfeld, Copenhagen, Denmark.9 
This assay measured porcine CCK 33, sulfated CCK 8, and a portion of CCK 39. The 
hallmark of this assay was the use of a nonoxidative radiolabeling technique to create a 
suitable I125 tracer, which was found to have the same immunoreactivity as native CCK 
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33.9 This non-oxidative radiolabeling technique involves conjugation of an I125 ester to 
two of the free NH2 groups on the lysyl side chains of CCK.9 An antiserum was raised 
against CCK 33 in guinea pigs and rabbits through injection of purified porcine CCK 33. 
The result was the development of the first sensitive and reliable RIA for CCK.9  
In 1983, Jansen and Lamers described one of the first assays with adequate 
specificity and sensitivity to accurately measure CCK in human plasma.11 Similar to the 
Rehfeld assay; they used porcine CCK 33 as a standard, and also as a stimulus for 
antibody production in both guinea pigs and rabbits. A major flaw of this assay was that 
their antibody did not reliably bind to CCK peptides with less than 14 amino acid 
residues.11 This limitation is of great significance as we know today that CCK 8 has a 
major biological role in the gastrointestinal tract. However, this assay was highly 
sensitive for CCK, showed no cross-reactivity with gastrin, and was shown to be capable 
of accurately measuring CCK in human tissue and plasma.11 This report was also among 
the first to describe that the infusion of exogenous CCK results in pancreatic enzyme 
secretion and gallbladder contraction in humans.11  
Around the same time as the previous assays, other assays for CCK were under 
development.12 Like the previous assays they also measured CCK 33, both in humans 
and also dogs. However, similar to the Jansen and Lamers assay, these RIAs did not 
reliably measure CCK 8.12  
In 1988, yet another CCK RIA was described by Ohgo et al.; this assay was the 
first to use an antiserum produced from sulfated CCK 8 injected into rabbits.13 This 
assay was used to measure CCK in human plasma before and after a meal. It was found 
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that CCK increased as much as 4 fold following ingestion of a test meal.13 They also 
showed that their antibody bound CCK 39, CCK 33, and CCK 8 with equimolar 
potency.13  
In 1998, the early CCK RIAs were improved by the production of a highly 
specific CCK antiserum, antibody 92128. This antibody proved to bind sulfated CCK 8, 
CCK 22, CCK 33, and CCK 58 with equimolar potency, and showed no cross-reactivity 
with gastrin, a problem that had plagued all previous CCK RIA antisera to some 
degree.10 Binding with equimolar potency allows the measurement of the major 
biologically active forms of CCK simultaneously, instead of individually, allowing for a 
more accurate measurement and estimation of total plasma CCK concentration. Thus, a 
single assay for the accurate measurement of cholecystokinin in plasma had been 
described using a highly specific antibody.10 This same antibody was generously 
supplied to the Gastrointestinal Laboratory at Texas A&M University by Jens Rehfeld, 
Copenhagen, Denmark, for use in the development of a CCK radioimmunoassay for 
dogs.  
As of 2013, there are several commercial RIA and ELISA kits available for the 
measurement of CCK. However, to our knowledge, none of these assays have been 
analytically validated for use with canine serum. Thus, the objectives of this study were 
to modify the RIA for measurement of serum CCK in humans described by Rehfeld for 
use in dogs without using human reagents, and to analytically validate this modified 
immunoassay for use with canine serum.10 This work will allow future studies on the 
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role and biological function of CCK in the dog, and in dogs with suspected alterations in 
CCK secretion.  
 
CLINICAL APPLICATION 
To date, there are no assays that have been analytically validated for use with 
canine serum. Being able to accurately measure CCK in dog serum is important to 
determine alterations in CCK secretion in dogs with gastrointestinal disease. In humans, 
alterations in CCK secretion have been described in patients with celiac disease, chronic 
pancreatitis, hepatic cirrhosis, Nelson’s disease, and Cushing’s disease11,14,15,16,17,18 
Increased plasma CCK concentrations in patients with chronic pancreatitis have been 
reported in the literature.16 Increased plasma CCK concentrations in patients with  
hepatic cirrhosis have also been reported in the literature.17 Large amounts of CCK have 
been found in pituitary adenomas of patients with Nelson´s syndrome and some patients 
with Cushing´s disease.18 
 
OBJECTIVE 
While there is a wealth of information on CCK and alterations of CCK secretion 
in humans, there is a distinct lack of information on similar abnormalities in dogs. This 
is likely due to the complexity of the commonly used RIAs, their antiserum, and their 
inclusion of human reagents, which require special permits, safety precautions, and 
clearance by the governing bodies of the laboratory. In order to measure CCK in dogs, 
an analytically validated assay for this species and sample type (serum, plasma, whole 
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blood) to be used should exist before reliable and reproducible measurements can be 
made. This will then allow studies to be conducted in order to determine if a clinical 
disorder might be a result of an abnormal CCK secretion. The assay proposed here 
would allow for continued research without the issues associated with using human 
reagents, or in using an assay protocol that has not been analytically validated for use 
with canine serum. 
The research plan was to establish the original protocol as described by Rehfeld 
at the Gastrointestinal Laboratory at Texas A&M University, changing steps sequentially 
in order to modify the assay to remove all human reagents.10 The human reagents to be 
removed are human plasma and 5% human serum albumin. Changes made to the 
original protocol included: the transition from plasma samples to serum samples, a 
change of incubation time from 7 days to 3 days, the use of canine plasma instead of 













MODIFICATION OF RADIOIMMUNOASSAY 
 
INTRODUCTION 
The first step in the process of developing a canine CCK radioimmunoassay was 
the modification of the assay for use in humans described by Jens F. Rehfeld, Dept. of 
Clinical Biochemistry, Rigshospitalet, DK-2100 Copenhagen, Denmark. After several 
successful runs using the original protocol, all human reagents were sequentially 
replaced with reagents of either canine or bovine origin. The resulting sets of reagents 
were tested for agreement with the original assay. The original radioimmunoassay uses 
human plasma and human albumin, both of which require special handling and disposal 
procedures, as well as special permits, which were among the main reasons these 
reagents were selected for replacement. The following sections detail the process of 
assay modification from the original protocol up until the working protocol was 
established prior to analytical validation.  
 
MATERIALS AND METHODS 
 Materials - All commonly used research materials and supplies were obtained 
from VWR Scientific, West Chester, PA. Radiolabeled I125CCK-8 was purchased from 
Perkin Elmer, Waltham, MA (NEX203010UC) in 10 µCi amounts and used until its 
expiration date. Synthetic sulfated CCK-8 used for making standards was purchased 
from Sigma-Aldrich, St. Louis, MO (C2175) and immediately reconstituted, diluted to a 
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8 nM stock solution, aliquoted, and stored at -20°C. Antibody 92128-5 was obtained by 
generous donation from Professor Jens F. Rehfeld, Dept. of Clinical Biochemistry, 
Rigshospitalet, DK-2100 Copenhagen, Denmark. Anti-CCK-8 was purchased from 
Sigma-Aldrich, St. Louis, MO (C2581). Activated charcoal used in the separation 
solution was purchased from Sigma-Aldrich, St. Louis, MO (C7606) and stored at room 
temperature until use. Thimerosal, used in Barbital Buffer I, was purchased from Sigma-
Aldrich, St. Louis, MO (T4687) and stored at room temperature until further use. 
Sodium azide, used in barbital buffer II, was purchased from Sigma-Aldrich, St. Louis, 
MO (S8032) and stored at room temperature until use. Barbital for use in the RIA 
buffers was purchased from Sigma-Aldrich, St. Louis, MO (B0375) via usage 
certification from the Large Animal Pharmacy at the Texas A&M University College of 
Veterinary Medicine. Canine serum albumin was purchased from Equitech-Bio, Inc., 
Kerrville, TX (CASA62) or purified from canine plasma using an ÄKTA Fast Protein 
Liquid Chromatography purification system with Hi-Trap Blue HP columns, all 
purchased from GE Life Sciences, Pittsburgh, PA. Canine fresh frozen plasma was 
purchased from Animal Blood Resources International, Dixon, CA, or obtained through 
use of outdated bags from the Veterinary Medical Teaching Hospital at Texas A&M 
University. Bovine serum albumin was purchased from Milipore, Billerica, MA (Cat # 
126593). Newborn calf serum was purchased from Sigma-Aldrich, St. Louis, MO 
(N4637). Human fresh frozen plasma was purchased from SeraCare Life Sciences, 
Milford, MA (23D00). Human serum albumin was purchased from CSL Behring, King 
of Prussia, PA (44206-251-05). Amicon Ultra-15 50 kDa centrifugal filters were 
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purchased from Milipore, Billerica, MA. The gamma counter used (1470 Wallac 
Wizard) was purchased from Perkin Elmer, Waltham, MA. The gel electrophoresis 
system used for SDS-PAGE was purchased from Life Technologies, Grand Island, NY. 
The gel used for estimation of purity and molecular weight was a NuPAGE Bis-Tris 
10% MiniGel purchased from Life Technologies, Grand Island, NY.   
 Original Protocol - To establish the assay protocol received from Dr. Jens 
Rehfeld, Copenhagen, Denmark, a 25% human albumin solution was combined with 
deionized water in a 1:5 ratio creating a 5% human albumin solution. Four-hundred µL 
aliquots of the 5% human albumin solution were transferred to 2 mL sample tubes. 
Eight-hundred µL of 96% (vol/vol) ethanol were pipetted into each 400 µL albumin 
aliquot. The aliquots were intermittently vortexed for 10 seconds each. After vortexing, 
all tubes were centrifuged for 15 minutes at 4,000 rpm and room temperature. The 
resulting clear supernatant was decanted from each tube into a fresh sample tube. The 
supernatants were then evaporated at room temperature in a vacuum concentrator for 5 
hours. These extracts were then reconstituted to their original 400 µL volume with either 
standards or controls. For each assay run 13 human albumin extracts were used: one 
each for the nonspecific binding tubes and the total binding tubes, one each for the 8 
standards, and one each for the 3 controls. Barbital buffers I (20 mM barbital, 0.6 mM 
thimerosal, 0.11% human albumin, pH 8.4) and II (20 mM barbital, 0.13 g/L sodium 
azide, pH 8.4) were used as buffers for the assay: both buffers were filtered through a 0.2 
µm filter and degassed. Barbital buffer I was used as an RIA buffer, and for dilutions and 
reconstitutions. Barbital buffer II was used as a separation solution for the measurement 
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of bound vs. unbound CCK concentration. After the buffers were prepared, standards 
were made using commercially available synthetic sulfated CCK-8. One mg of CCK-8 
was reconstituted in 10 mL of barbital buffer I. The resulting 8.8 µM solution was 
diluted to 8x10-10 M using barbital buffer I to make a working solution. Standards of 1, 
2.5, 5, 10, 20, 30, and 50 pM were made from the standard working solution. Four, 7.5, 
and 15 pM controls were also made from this standard working solution. Each standard 
was raised to the desired volume using barbital buffer I as the diluent. Antibodies were 
diluted using barbital buffer I from 10 µL aliquots of antibody 92128-5, which was 
originally reconstituted into 250 µL of pure water. To carry out the assay, the RIA was 
set up in duplicate fashion with two tubes for each preparation (total count, non-specific 
binding, total binding, standards, controls, and samples). On the day of the assay, 
antibody 92128-5, albumin extracts, standards, and controls were taken out of the freezer 
and thawed at room temperature. Barbital buffer I was taken out of the 4°C refrigerator 
and allowed to warm to room temperature (approximately 22°C). RIA tubes were 
arranged and labeled. RIA tracer was taken from the freezer and diluted with barbital 
buffer I to 1,000 cpm +/- 100 cpm based on gammacounter readings for 60 seconds. 
Barbital buffer I was placed in each tube in the respective amounts as described in 
Figure 1. Albumin extracts were reconstituted to 400 µL with standard and control 
solutions, and then added to each tube in an amount as described in Figure 1. Antibody 
92128-5 was diluted to the desired concentration using barbital buffer I, and then added 
to each tube in an amount as described in Figure 1. All tubes were then taken to a 
separate radiation room where 100 µL of tracer were added to each tube. All tubes were  
  
 16 
Figure 1 – RIA setup. This figure shows reagent volumes required for the RIA setup as 
described in the original protocol. All tubes are set-up and assayed in duplicate fashion. 
The 0 sample is one of the extract tubes filled with buffer. 
 
  Reference: 
   TC:  1,300 µL Barbital Buffer I 
     100 µL Tracer 
 
   NSB:  1,150 µL Barbital Buffer I 
     150 µL 0 Sample 
     100 µL Tracer 
 
   TB:  1,000 µL Barbital Buffer I 
     150 µL 0 Sample 
     150 µL Antibody 
     100 µL Tracer 
 
  Standards/Controls/Samples: 
   Std/Control: 1,000 µL Barbital Buffer I 
     150 µL Standard/Control 
     150 µL Antibody 
     100 µL Tracer 
 
   Sample:  1,000 µL Barbital Buffer I 
     150 µL Sample 
     150 µL Antibody 




vortexed and allowed to incubate for 7 days at 4°C. On day 7, a separation solution was 
prepared using 80 mL barbital buffer II, 20 mL of human plasma, and 6 g of activated 
charcoal. The solution was kept on ice while being vigorously mixed with a magnetic 
stirrer for 30 minutes. After 30 minutes, 500 µL of separation solution was added to each 
tube. All tubes were vortexed and allowed to incubate at room temperature for 15 to 30 
minutes. All tubes were then centrifuged for 10 minutes at 4,000 rpm and 4°C. The 
supernatants from all tubes (except TC tubes) were transferred from the original tube to 
a new tube, tapping once. The supernatant tubes were counted in an automatic 
gammacounter for 5 minutes. Counts per minute (cpm) were measured for all tubes. The 
cpm data was entered into an Excel® spreadsheet where average, standard deviation, 
correlation of variance, and B/B0 were calculated. B/B0 was calculated using the 
formula: B/B0 = (B - NSB) / (B0 - NSB), where B is the count of the supernatant and B0 
the count of the total binding (TB). A four-parameter log-logistic (4PL) standard curve 
was generated in Prism 6® by plotting the logarithm of the concentration against B/B0. 
All unknown values were extrapolated based on the standard curve. 
After the original protocol was established, the following changes were made to 
the protocol to facilitate the measurement of CCK in canine serum: human plasma in the 
separation solution was replaced with canine fresh frozen plasma, human serum albumin 
in the albumin extracts and barbital buffer I were replaced with bovine serum albumin, 
canine albumin, or newborn calf serum, and the incubation time of the assay was 
decreased from 7 days to 3 days. Success was determined through comparison of an 
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assay run with and without the proposed changes. The materials and methods used to 
modify the assay are outlined as follows:  
 Sigma Anti-CCK-8 - After establishing the original protocol, a commercial 
antibody for CCK was purchased from Sigma Aldrich. Antibody 92128-5 that was 
received from Jens Rehfeld is only available in a limited amount. As a proactive step to 
avoid running out of the original antibodies, the commercial antibody against CCK was 
purchased and used in an attempt to replace the original antibody. The assay was carried 
out using the protocol described above, with the addition of the following steps: Sigma 
anti-CCK-8 was reconstituted and diluted to the desired concentrations for testing 
binding percentage, and run in comparison to antibody 92128-5 in the same assay runs. 
 Canine Plasma - After finding suitable antibody dilutions for antibody 92128-5 
and Sigma anti-CCK-8, the next step in modifying the original assay was to try to 
replace all human reagents with non-human reagents. The assay was carried out using 
the protocol described above, with the addition of the following steps: human plasma in 
the separation solution was replaced with canine fresh frozen plasma. Also, Sigma anti-
CCK-8 was used instead of antibody 92128-5. 
 Canine Albumin Purification - Due to an indefinite backorder of canine 
albumin, the expense of the limited quantities that were available, and the need to 
replace all human reagents with canine reagents, the decision was made to purify canine 
albumin using FPLC. Canine fresh frozen plasma was thawed at room temperature. 
After thawing, 5 mL plasma aliquots were filtered through 0.8 µm, 0.45 µm, and 0.2 µm 
syringe filters, and then frozen at -20°C for future use. A binding buffer (50 mM 
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KH2PO4, pH 7.0) and an elution buffer (50 mM KH2PO4, 1.5 M KCl, pH 7.0) were 
prepared, filtered at 0.2 µm, and degassed. A storage solution consisting of 0.1 M 
KH2PO4 and 20% ethanol was made and used to store columns, when not in use, at 4°C. 
Five mL of 0.2 µm filtered canine plasma was thawed and diluted 1:2 with binding 
buffer immediately before use. The FPLC ÄKTA Purifier was set up with three 5 mL Hi 
Trap Blue HP columns connected in series to scale up operation. Binding buffer was 
introduced to the columns at 5 mL per minute to wash out the preservative and storage 
solution. The columns were then equilibrated with 5 column volumes of binding buffer 
(75 mL) at a rate of 5 mL per minute. Ten mL of diluted and filtered canine plasma was 
injected onto the columns at a rate of 5 mL per minute. The columns were then eluted 
with 5 column volumes (75 mL) of elution buffer at a rate of 5 mL per minute and 
collected as 5 mL fractions until no more material appeared in the effluent. The elution 
buffer was washed out with storage solution and all columns were stored at 4°C until 
use. All secondary peak fractions were collected and combined. Secondary peak 
fractions were divided among 4 Amicon Ultra-15 50 kDa centrifugal filters and placed in 
swinging bucket rotors and centrifuged at 4,000 x g and 25°C for 15 minutes. The eluent 
beneath the filter was discarded and 1X PBS, pH 7.4 was added to raise the concentrated 
solution remaining in the filter to its original volume. Three more centrifugations were 
carried out in this fashion and the remaining 4 100-500 µL canine albumin concentrates 
were combined and frozen at -80°C. The combined frozen concentrate was placed in a 
lyophilizer and allowed to freeze-dry until no moisture remained. Approximate albumin 
concentrations were determined using Nanodrop, Bradford, and Ultrospec 2000. SDS-
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PAGE with a NuPAGE 10% Bis-Tris 10 well mini-gel was used with 1X MOPS and 
SeeBlue +2 and Mark 12 standards to determine the presence of canine albumin and 
estimate its approximate purity. FPLC runs and purification were continued until enough 
canine albumin was obtained to test assay compatibility. The freeze-dried canine 
albumin was reconstituted with 1X PBS, pH 7.4 before use.  
 Barbital Buffer I with Canine Albumin - The next step in modifying the 
original assay was replacing human albumin in barbital buffer I with canine albumin 
obtained from FPLC. The assay was carried out using the protocol described above, with 
the addition of the following steps: Sigma anti-CCK-8 was used in conjunction with 
antibody 92128-5, and 0.55 g of canine albumin was used instead of human albumin in a 
fresh 500 mL batch of barbital buffer I. Ten canine samples were obtained and extracted 
using the methods in the original protocol. The samples were used to compare the 
effectiveness of both antibodies, and to verify that canine albumin was a viable 
replacement for human albumin. Four-hundred µL aliquots of each sample were 
transferred into 2 mL sample tubes. Eight hundred µL of 96% (vol/vol) ethanol was then 
pipetted into each 400 µL albumin aliquot. The aliquots were then intermittently 
vortexed for 10 seconds each. After vortexing, the tubes were centrifuged for 15 minutes 
at 4,000 rpm and room temperature. The resulting clear supernatant was decanted from 
each tube into a fresh sample tube. The supernatants were evaporated at room 
temperature in a vacuum concentrator for 5 hours. Another 800 µL of 96% (vol/vol) 
ethanol was pipetted into each dried 400 µL albumin aliquot and dried for another 5 
hours. These sample extracts were then reconstituted to their original 400 µL volume 
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with barbital buffer I or stored at -20°C until use. Several assay runs were performed 
using the original protocol to compare the two antibodies and canine albumin versus 
human albumin in barbital buffer I. 
 7 Versus 3 Day Incubation - Seven day RIA incubations were becoming a 
hindrance to the project, so steps were taken to decrease the incubation time. The assay 
was carried out using the protocol described above, with the addition of the following 
steps: canine albumin was used instead of human albumin in barbital buffer I, canine 
plasma was used instead of human plasma in the separation solution, both 3 and 7 day 
incubations were used, and a 1:20,000 antibody 92128-5 dilution was used. 
 New Barbital Buffer I - The canine albumin that had been purified using FPLC 
was determined to be produced in an amount that was insufficient for continued use 
based on the time required for purification. The decision was made to replace canine 
albumin in barbital buffer I with either newborn calf serum (NCS) or bovine serum 
albumin (BSA). The assay was carried out using the protocol described above, with the 
addition of the following steps: canine albumin, BSA, and NCS were used in separate 
solutions of barbital buffer I, canine plasma was used instead of human plasma in the 
separation solution, a 3 day incubation time was used instead of a 7 day incubation time, 
and a 1:20,000 antibody 92128-5 dilution was used. The BSA barbital buffer I was 
prepared using 1.1 g/L of bovine serum albumin. A NCS barbital buffer I was prepared 
using 0.11 % newborn calf serum. 
     Albumin Extracts - The final step in converting the original assay protocol 
was replacement of human albumin in the albumin extracts. BSA extracts were made by 
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adding 1 g of bovine serum albumin in 20 mL deionized water and then taking 400 µL 
aliquots of the 5% BSA solution and adding 800 µL of 96% (vol/vol) ethanol into each 
400 µL albumin aliquot. The aliquots were then intermittently vortexed for 10 seconds 
each. After vortexing, the tubes were centrifuged for 15 minutes at 4,000 rpm and room 
temperature. The resulting clear supernatant was decanted from each tube into a fresh 
sample tube. The supernatants were evaporated at room temperature in a vacuum 
concentrator for 5 hours. These albumin extracts were then reconstituted to their original 
400 µL volume with barbital buffer I, standards, or controls, or stored at -20°C until use. 
Newborn calf serum extracts were obtained by adding 1 mL of NCS in 20 mL deionized 
water and then taking 400 µL aliquots of the 5% NCS solution and adding 800 µL of 
96% (vol/vol) ethanol into each 400 µL NCS aliquot. The aliquots were then 
intermittently vortexed for 10 seconds each. After vortexing, the tubes were centrifuged 
for 15 minutes at 4,000 rpm and room temperature. The resulting clear supernatant was 
decanted from each tube into a fresh sample tube. The supernatants were then 
evaporated at room temperature into a vacuum concentrator for 5 hours. These NCS 
extracts were then reconstituted to their original 400 µL volume with barbital buffer I, 
standards, or controls, or stored at -20°C until further use. The assay was carried out as 
described above, with the addition of the following steps: barbital buffer I was made 
with canine albumin, NCS, or BSA as three separate barbital buffers, extracts used were 
human serum albumin extracts, NCS extracts, or BSA extracts, canine plasma was used 
in the separation solution, a 3 day incubation time was used, and a 1:20,000 antibody 




The optimal antibody dilution was determined for antibody 92128-5 using the 
original protocol (Table 1). Although the results of an antibody dilution assay run 
originally showed desired binding when using Sigma anti-CCK-8 (Table 2), antibody 
92128-5 was unsuccessfully replaced by Sigma anti-CCK-8 when the standard curve 
was generated and the samples were measured (Table 3). Human plasma in the 
separation solution was successfully replaced by canine fresh frozen plasma (Table 4). 
Canine albumin was purified by FPLC (Figs 2 and 3) and used in barbital buffer I to 
replace human serum albumin (Tables 5 and 6). Antibody 92128-5 was successfully 
used to measure canine samples with canine albumin in barbital buffer I and canine 
plasma in the separation solution (Table 6). A 3-day assay incubation time was 
determined to be equivalent to a 7-day incubation time (Table 7). Newborn calf serum 
was used to replace canine albumin in barbital buffer I (Table 8). Newborn calf serum 
was used to replace human albumin in the albumin extracts (Table 9). A typical standard 










Table 1 – Determination of optimal antibody dilution. This table shows the results of an 
assay run using antibody 92128-5 at different dilutions, barbital buffer I with human 
albumin, human albumin extracts, and human plasma in the separation solution. This 
table shows the results for determining an antibody dilution that would result in 
approximately 40% binding. Binding percent (B%) is calculated by dividing the average 
cpm (counts per minute) of the antibody dilution by the average cpm of the TC (total 
count) and multiplying by 100. (SD = standard deviation; %CV = coefficient of 
variation).   
 
 
Tube%ID% Tube%1% Tube%2% Mean% SD% %CV% B%%
%% cpm% cpm% cpm% cpm% %% %%
TC% 1029.7% 1009.9% 1019.8% 14.0% 1.4% %%
NSB% 22.1% 24.1% 23.1% 1.4% 6.1% %%
1:10,000% 591.8% 574.2% 583.0% 12.4% 2.1% 57.2%
1:15,000% 449.2% 457.7% 453.5% 6.0% 1.3% 44.5%
1:20,000% 357.6% 382.4% 370.0% 17.5% 4.7% 36.3%















Table 2 – Determination of optimal commercial antibody dilution. This table shows the 
results of an assay run using Sigma anti-CCK-8 at different dilutions, barbital buffer I 
with human albumin, human albumin extracts, and human plasma in the separation 
solution. This figure shows the results for determining an antibody dilution that would 
result in approximately 75% binding. Binding percent (B%) is calculated by dividing the 
average cpm (counts per minute) of the antibody dilution by the average cpm of the TC 






Tube%ID% Tube%1% Tube%2% Mean% SD% %CV% B%%
%% cpm% cpm% cpm% cpm% %% %%
TC% 968.9% 963.7% 966.3% 3.7% 0.4% %%
NSB% 25.6% 27.8% 26.7% 1.6% 5.8% %%
1:5,000% 804.3% 774.4% 789.4% 21.1% 2.7% 81.7%
1:10,000% 789.5% 780.7% 785.1% 6.2% 0.8% 81.2%
1:20,000% 769.0% 813.0% 791.0% 31.1% 3.9% 81.9%
1:40,000% 754.7% 755.3% 755.0% 0.4% 0.1% 78.1%
1:80,000% 672.5% 704.4% 688.5% 22.6% 3.3% 71.2%
1:160,000% 511.4% 512.6% 512.0% 0.8% 0.2% 53.0%
1:320,000% 359.1% 331.0% 345.1% 19.9% 5.8% 35.7%











Table 3 – Use of Sigma anti-CCK-8 antibody for generation of a standard curve. This 
table shows the results of an assay run using Sigma anti-CCK-8 at a 1:60,000 dilution 
with standards and controls, barbital buffer I with human albumin, human albumin 
extracts, and canine plasma in the separation solution. B/B0 is calculated by subtracting 
the average non-specific binding (NSB) cpm (counts per minute) from the average cpm 
of the standards, and dividing by the average cpm of the TB (total binding) minus the 
NSB cpm. This number is multiplied by 100 to get the percent binding (B%; which is 
the binding percent relative to TB). (Std = standard; Ctrl = control; SD = standard 





Tube%ID% Nominal% Tube%1% Tube%2% Mean% SD% %CV% B/B0% B%% CCK%
%% pM% cpm% cpm% cpm% cpm% %% %% %% pM%
TC% %% 1007.5% 1065.8% 1036.7% 41.2% 4.0% %% %% %%
NSB% %% 28.1% 29.0% 28.6% 0.6% 2.2% %% %% %%
TB% %% 820.4% 806.3% 813.4% 10.0% 1.2% 1.0% 100.0% %%
Std%1% 1.0% 799.4% 799.4% 799.4% 0.0% 0.0% 1.0% 98.2% %%
Std%2% 2.5% 778.2% 766.0% 772.1% 8.6% 1.1% 0.9% 94.7% %%
Std%3% 5.0% 781.7% 773.6% 777.7% 5.7% 0.7% 1.0% 95.5% %%
Std%4% 10.0% 760.6% 750.5% 755.6% 7.1% 0.9% 0.9% 92.6% %%
Std%5% 20.0% 675.9% 649.3% 662.6% 18.8% 2.8% 0.8% 80.8% %%
Std%6% 30.0% 625.1% 686.2% 655.7% 43.2% 6.6% 0.8% 79.9% %%
Std%7% 50.0% 568.7% 556.5% 562.6% 8.6% 1.5% 0.7% 68.0% %%
Ctrl%1% 4.0% 760.8% 738.8% 749.8% 15.6% 2.1% 0.9% 91.9% 8.2%
Ctrl%2% 7.5% 737.8% 732.6% 735.2% 3.7% 0.5% 0.9% 90.0% 10.7%









Table 4 – Removal of human plasma from the separation solution. This table shows the 
results of an assay run using Sigma anti-CCK-8 at different dilutions, barbital buffer I 
with human albumin, human albumin extracts, and canine plasma in the separation 
solution. Binding percent (B%) is calculated by dividing the average cpm (counts per 
minute) of the dilution by the average cpm of the TC (total count) and multiplying by 
100. (SD = standard deviation; %CV = coefficient of variation).  
 
 
Tube%ID% Tube%1% Tube%2% Mean% SD% %CV% B%%
%% cpm% cpm% cpm% cpm% %% %%
TC% 1139.9% 1092.5% 1116.2% 33.5% 3.0% %%
NSB% 28.3% 30.5% 29.4% 1.6% 5.3% %%
1:40,000% 738.4% 771.1% 754.8% 23.1% 3.1% 67.6%
1:60,000% 772.2% 776.7% 774.5% 3.2% 0.4% 69.4%




























































































































































































































































































































































































































































































































Figure 3 – SDS-PAGE of partially purified canine albumin. This NuPAGE 10% Bis-Tris 
gel was stained with Coomassie blue. A molecular weight standard was loaded into lane 
1. An FPLC flow-through peak was loaded into lane 2. An FPLC eluent peak was loaded 
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Table 5 – Sigma anti-CCK-8 with standards and samples. This table shows the results of 
an assay run using Sigma anti-CCK-8 at a 1:60,000 dilution with standards/controls and 
samples, barbital buffer I with canine albumin, human albumin extracts, and canine 
plasma in the separation solution. Several serum samples from healthy dogs were 
included in this assay run. B/B0 is calculated by subtracting the average non-specific 
binding (NSB) cpm (counts per minute) from the average cpm of the standards, and 
dividing by the average cpm of the TB (total binding) minus the NSB cpm. This number 
is multiplied by 100 to get the percent binding (B%; which is the binding percent relative 
to TB). (Std = standard; Ctrl = control; SD = standard deviation; %CV = coefficient of 
variation; CCK = CCK concentration). 
 
 
Tube%ID% Nominal% Tube%1% Tube%2% Mean% SD% %CV% B/B0% B%% CCK%
%% pM% cpm% cpm% cpm% cpm% %% %% %% pM%
TC% %% 1134.3% 1132.8% 1133.6% 1.1% 0.1% %% %% %%
NSB% %% 25.1% 25.1% 25.1% 0.0% 0.0% %% %% %%
TB% %% 734.2% 803.4% 768.8% 48.9% 6.4% 1.0% 100.0% %%
Std%1% 1.0% 748.7% 767.9% 758.3% 13.6% 1.8% 1.0% 98.6% %%
Std%2% 2.5% 792.3% 766.4% 779.4% 18.3% 2.3% 1.0% 101.4% %%
Std%3% 5.0% 760.6% 733.9% 747.3% 18.9% 2.5% 1.0% 97.1% %%
Std%4% 10.0% 720.4% 687.9% 704.2% 23.0% 3.3% 0.9% 91.3% %%
Std%5% 20.0% 648.7% 654.4% 651.6% 4.0% 0.6% 0.8% 84.2% %%
Std%6% 30.0% 627.7% 625.0% 626.4% 1.9% 0.3% 0.8% 80.8% %%
Std%7% 50.0% 580.5% 566.1% 573.3% 10.2% 1.8% 0.7% 73.7% %%
Ctrl%1% 4.0% 704.2% 759.5% 731.9% 39.1% 5.3% 1.0% 95.0% 7.1%
Ctrl%2% 7.5% 738.1% 729.7% 733.9% 5.9% 0.8% 1.0% 95.3% 6.8%
Ctrl%3% 15.0% 706.0% 736.5% 721.3% 21.6% 3.0% 0.9% 93.6% 8.6%
Sample%1% %% 804.8% 797.8% 801.3% 4.9% 0.6% 1.0% 104.4% %%
Sample%2% %% 824.4% 819.5% 822.0% 3.5% 0.4% 1.1% 107.1% %%
Sample%3% %% 789.8% 799.4% 794.6% 6.8% 0.9% 1.0% 103.5% %%
Sample%4% %% 776.9% 795.0% 786.0% 12.8% 1.6% 1.0% 102.3% %%
Sample%5% %% 821.3% 830.1% 825.7% 6.2% 0.8% 1.1% 107.7% %%
Sample%6% %% 748.2% 764.8% 756.5% 11.7% 1.6% 1.0% 98.3% 3.4%
Sample%7% %% 820.5% 808.9% 814.7% 8.2% 1.0% 1.1% 106.2% %%
Sample%8% %% 826.7% 850.5% 838.6% 16.8% 2.0% 1.1% 109.4% %%
Sample%9% %% 765.5% 803.7% 784.6% 27.0% 3.4% 1.0% 102.1% %%
Sample%10% %% 796.8% 829.3% 813.1% 23.0% 2.8% 1.1% 105.9% %%
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Table 6 – Antibody 92128-5 with standards and samples. This table shows the results of 
an assay run using antibody 92128-5 at a 1:20,000 dilution with standards/controls and 
samples, barbital buffer I with canine albumin, human albumin extracts, and canine 
plasma in the separation solution. Several serum samples from healthy dogs were 
included in this assay run. B/B0 is calculated by subtracting the average non-specific 
binding (NSB) cpm (counts per minute) from the average cpm of the standards, and 
dividing by the average cpm of the TB (total binding) minus the NSB cpm. This number 
is multiplied by 100 to get the percent binding (B%; which is the binding percent relative 
to TB). (Std = standard; Ctrl = control; SD = standard deviation; %CV = coefficient of 
variation; CCK = CCK concentration). 
 
 
Tube%ID% Nominal% Tube%1% Tube%2% Mean% SD% %CV% B/B0% B%% CCK%
%% pM% cpm% cpm% cpm% cpm% %% %% %% pM%
TC% %% 1095.5% 1101.8% 1098.7% 4.5% 0.4% %% %% %%
NSB% %% 27.7% 31.8% 29.8% 2.9% 9.7% %% %% %%
TB% %% 455.2% 443.5% 449.4% 8.3% 1.8% 1.0% 100.0% %%
Std%1% 1.0% 411.0% 391.0% 401.0% 14.1% 3.5% 0.9% 88.5% %%
Std%2% 2.5% 346.4% 373.3% 359.9% 19.0% 5.3% 0.8% 78.7% %%
Std%3% 5.0% 291.5% 287.0% 289.3% 3.2% 1.1% 0.6% 61.8% %%
Std%4% 10.0% 217.2% 222.9% 220.1% 4.0% 1.8% 0.5% 45.4% %%
Std%5% 20.0% 153.9% 160.4% 157.2% 4.6% 2.9% 0.3% 30.4% %%
Std%6% 30.0% 119.6% 131.5% 125.6% 8.4% 6.7% 0.2% 22.8% %%
Std%7% 50.0% 88.2% 97.0% 92.6% 6.2% 6.7% 0.1% 15.0% %%
Ctrl%1% 4.0% 303.2% 323.1% 313.2% 14.1% 4.5% 0.7% 67.5% 4.0%
Ctrl%2% 7.5% 243.3% 238.2% 240.8% 3.6% 1.5% 0.5% 50.3% 8.3%
Ctrl%3% 15.0% 197.6% 182.0% 189.8% 11.0% 5.8% 0.4% 38.1% 13.7%
Sample%1% %% 391.8% 384.5% 388.2% 5.2% 1.3% 0.9% 85.4% 1.4%
Sample%2% %% 381.2% 405.8% 393.5% 17.4% 4.4% 0.9% 86.7% 1.3%
Sample%3% %% 392.3% 432.2% 412.3% 28.2% 6.8% 0.9% 91.2% 0.8%
Sample%4% %% 336.5% 320.5% 328.5% 11.3% 3.4% 0.7% 71.2% 3.4%
Sample%5% %% 399.1% 395.2% 397.2% 2.8% 0.7% 0.9% 87.6% 1.2%
Sample%6% %% 330.7% 330.5% 330.6% 0.1% 0.0% 0.7% 71.7% 3.3%
Sample%7% %% 387.9% 386.2% 387.1% 1.2% 0.3% 0.9% 85.2% 1.5%
Sample%8% %% 406.1% 403.3% 404.7% 2.0% 0.5% 0.9% 89.4% 1.0%
Sample%9% %% 359.8% 356.1% 358.0% 2.6% 0.7% 0.8% 78.2% 2.3%




Table 7 – Assay run with 3 day incubation. This table shows the results of an assay run 
using antibody 92128-5 at a 1:20,000 dilution with standards/controls and samples, 
barbital buffer I with canine albumin, human albumin extracts, canine plasma in the 
separation solution, and a 3 day incubation time. Several serum samples from healthy 
dogs were included in this assay run. B/B0 is calculated by subtracting the average non-
specific binding (NSB) cpm (counts per minute) from the average cpm of the standards, 
and dividing by the average cpm of the TB (total binding) minus the NSB cpm. This 
number is multiplied by 100 to get the percent binding (B%; which is the binding 
percent relative to TB). (Std = standard; Ctrl = control; SD = standard deviation; %CV = 
coefficient of variation; CCK = CCK concentration). 
 
 
Tube%ID% Nominal% Tube%1% Tube%2% Mean% SD% %CV% B/B0% B%% CCK%
%% pM% cpm% cpm% cpm% cpm% %% %% %% pM%
TC% %% 951.3% 970.0% 960.7% 13.2% 1.4% %% %% %%
NSB% %% 18.1% 24.1% 21.1% 4.2% 20.1% %% %% %%
TB% %% 427.8% 401.2% 414.5% 18.8% 4.5% 1.0% 100.0% %%
Std%1% 1.0% 374.1% 379.8% 377.0% 4.0% 1.1% 0.9% 90.5% %%
Std%2% 2.5% 312.4% 325.9% 319.2% 9.5% 3.0% 0.8% 75.8% %%
Std%3% 5.0% 247.1% 262.6% 254.9% 11.0% 4.3% 0.6% 59.4% %%
Std%4% 10.0% 203.4% 204.9% 204.2% 1.1% 0.5% 0.5% 46.5% %%
Std%5% 20.0% 153.1% 147.5% 150.3% 4.0% 2.6% 0.3% 32.8% %%
Std%6% 30.0% 110.7% 112.5% 111.6% 1.3% 1.1% 0.2% 23.0% %%
Std%7% 50.0% 75.4% 83.9% 79.7% 6.0% 7.5% 0.1% 14.9% %%
Ctrl%1% 4.0% 287.4% 286.2% 286.8% 0.8% 0.3% 0.7% 67.5% 3.9%
Ctrl%2% 7.5% 218.2% 239.2% 228.7% 14.8% 6.5% 0.5% 52.8% 7.5%
Ctrl%3% 15.0% 167.8% 164.3% 166.1% 2.5% 1.5% 0.4% 36.8% 15.0%
Sample%1% %% 287.3% 284.6% 286.0% 1.9% 0.7% 0.7% 67.3% 3.9%
Sample%2% %% 365.6% 353.8% 359.7% 8.3% 2.3% 0.9% 86.1% 1.2%
Sample%3% %% 335.3% 364.2% 349.8% 20.4% 5.8% 0.8% 83.5% 1.5%
Sample%4% %% 379.5% 383.7% 381.6% 3.0% 0.8% 0.9% 91.6% 0.7%
Sample%5% %% 390.3% 364.8% 377.6% 18.0% 4.8% 0.9% 90.6% 0.8%
Sample%6% %% 353.3% 348.0% 350.7% 3.7% 1.1% 0.8% 83.8% 1.5%
Sample%7% %% 360.9% 361.5% 361.2% 0.4% 0.1% 0.9% 86.5% 1.2%
Sample%8% %% 320.1% 353.0% 336.6% 23.3% 6.9% 0.8% 80.2% 1.9%
Sample%9% %% 272.7% 283.3% 278.0% 7.5% 2.7% 0.7% 65.3% 4.3%
Sample%10% %% 360.0% 364.5% 362.3% 3.2% 0.9% 0.9% 86.7% 1.2%
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Table 8 – Barbital buffer I with newborn calf serum. This table shows the results of an 
assay run using antibody 92128-5 at a 1:20,000 dilution with standards/controls, barbital 
buffer I with newborn calf serum, human albumin extracts, canine plasma in the 
separation solution, and a 3 day incubation time. B/B0 is calculated by subtracting the 
average non-specific binding (NSB) cpm (counts per minute) from the average cpm of 
the standards, and dividing by the average cpm of the TB (total binding) minus the NSB 
cpm. This number is multiplied by 100 to get the percent binding (B%; which is the 
binding percent relative to TB). (Std = standard; Ctrl = control; SD = standard deviation; 
%CV = coefficient of variation; CCK = CCK concentration). 
 
 
Tube%ID% Nominal% Tube%1% Tube%2% Mean% SD% %CV% B/B0% B%% CCK%
%% pM% cpm% cpm% cpm% cpm% %% %% %% pM%
TC% %% 1067.8% 1053.1% 1060.5% 10.4% 1.0% %% %% %%
NSB% %% 22.0% 22.9% 22.5% 0.6% 2.8% %% %% %%
TB% %% 448.2% 434.3% 441.3% 9.8% 2.2% 1.0% 100.0% %%
Std%1% 1.0% 404.8% 395.9% 400.4% 6.3% 1.6% 0.9% 90.2% %%
Std%2% 2.5% 327.3% 337.2% 332.3% 7.0% 2.1% 0.7% 74.0% %%
Std%3% 5.0% 274.8% 296.2% 285.5% 15.1% 5.3% 0.6% 62.8% %%
Std%4% 10.0% 208.5% 204.3% 206.4% 3.0% 1.4% 0.4% 43.9% %%
Std%5% 20.0% 134.8% 141.0% 137.9% 4.4% 3.2% 0.3% 27.6% %%
Std%6% 30.0% 107.0% 119.5% 113.3% 8.8% 7.8% 0.2% 21.7% %%
Std%7% 50.0% 73.4% 71.8% 72.6% 1.1% 1.6% 0.1% 12.0% %%
Ctrl%1% 4.0% 313.2% 306.0% 309.6% 5.1% 1.6% 0.7% 68.6% 3.7%
Ctrl%2% 7.5% 230.2% 217.7% 224.0% 8.8% 3.9% 0.5% 48.1% 8.6%










Table 9 – Assay run with newborn calf serum extracts. This table shows the results of an 
assay run using antibody 92128-5 at a 1:20,000 dilution with standards/controls, barbital 
buffer I with newborn calf serum, newborn calf serum extracts, canine plasma in the 
separation solution, and a 3 day incubation time. B/B0 is calculated by subtracting the 
average non-specific binding (NSB) cpm (counts per minute) from the average cpm of 
the standards, and dividing by the average cpm of the TB (total binding) minus the NSB 
cpm. This number is multiplied by 100 to get the percent binding (B%; which is the 
binding percent relative to TB). (Std = standard; Ctrl = control; SD = standard deviation; 
%CV = coefficient of variation; CCK = CCK concentration). 
 
 
Tube%ID% Nominal% Tube%1% Tube%2% Mean% SD% %CV% B/B0% B%% CCK%
%% pM% cpm% cpm% cpm% cpm% %% %% %% pM%
TC% %% 1043.4% 1048.7% 1046.1% 3.7% 0.4% %% %% %%
NSB% %% 29.0% 28.6% 28.8% 0.3% 1.0% %% %% %%
TB% %% 428.0% 450.4% 439.2% 15.8% 3.6% 1.0% 100.0% %%
Std%1% 1.0% 382.3% 368.7% 375.5% 9.6% 2.6% 0.8% 84.5% %%
Std%2% 2.5% 313.7% 347.1% 330.4% 23.6% 7.1% 0.7% 73.5% %%
Std%3% 5.0% 263.5% 276.4% 270.0% 9.1% 3.4% 0.6% 58.8% %%
Std%4% 10.0% 210.7% 206.1% 208.4% 3.3% 1.6% 0.4% 43.8% %%
Std%5% 20.0% 151.2% 147.7% 149.5% 2.5% 1.7% 0.3% 29.4% %%
Std%6% 30.0% 115.1% 115.4% 115.3% 0.2% 0.2% 0.2% 21.1% %%
Std%7% 50.0% 85.8% 92.1% 89.0% 4.5% 5.0% 0.1% 14.7% %%
Ctrl%1% 4.0% 290.0% 305.0% 297.5% 10.6% 3.6% 0.7% 65.5% 3.7%
Ctrl%2% 7.5% 244.8% 230.1% 237.5% 10.4% 4.4% 0.5% 50.8% 7.3%









Figure 4 – A typical standard curve of the CCK RIA. This figure shows a typical four-
parameter log-logistic (4PL) standard curve generated in Prism 6®. The standard 
concentrations are: 1, 2.5, 5, 10, 20, 30 and 50 pM, which are plotted on the x-axis in a 
logarithmic scale. Zero pM was plotted as 1x10-14, the smallest non-zero value capable 
of being plotted by Prism 6. B% values are plotted on the y-axis and are calculated from 
B/B0 = (B - NSB) / (B0 - NSB), where B is the supernatant cpm, and B0 is the total 
binding (TB) cpm. All unknown values are extrapolated based on where their B/B0 falls 
along the standard curve. All unknown values were multiplied by a factor of 10,000 to 











 The original radioimmunoassay protocol was used to successfully determine the 
optimal dilution of antibody 92128-5 to an approximate tracer-antibody binding of 40%. 
Due to the limited supply of antibodies used in the original protocol, a commercial 
antibody against CCK (Sigma anti-CCK-8) was purchased and compared to the original 
antibody. A 1:60,000 Sigma anti-CCK-8 dilution was determined to be ideal with a 
tracer-antibody binding of approximately 70%. The antibody dilutions were repeated and 
used to test the replacement of human plasma with canine plasma in the separation 
solution. No obvious differences were observed between the binding percentages of the 
assay runs with human plasma and canine plasma. Due to an indefinite backorder of 
canine albumin, canine albumin was purified from canine plasma using affinity-
chromatography FPLC columns, molecular weight centrifugal filters, and lyophilization. 
The purified canine albumin was used to replace human albumin in barbital buffer I. 
After testing the purified canine albumin in barbital buffer I with the Sigma anti-CCK-8 
antibodies, it was noted that the binding percentages among standards were non-sensible 
in that similar binding percentages were observed with standards of very different 
concentrations. Thus, the commercial antibodies (Sigma anti-CCK-8) were not useful to 
establish a standard curve and a decision was made to progress with the original 
antibodies for all subsequent assay runs due to desired binding and separation in the 
standards and samples. The results of the 7 versus 3 day incubation time showed no 
obvious differences between the two incubation times. Due to the dramatic time-savings, 
the 3 day incubation time was used for all subsequent assay runs. The results of the 
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albumin extract assay run showed no obvious difference between human albumin or 
NCS in the albumin extracts. Thus, newborn calf serum was used to produce the albumin 
extracts for all subsequent assay runs. The assay protocol, now in its final form, was 






















VALIDATION OF A CANINE CHOLECYSTOKININ RADIOIMMUNOASSAY 
 
INTRODUCTION 
  After successfully replacing all human reagents in the original CCK assay 
protocol with reagents of either canine or bovine origin, the adapted protocol had to be 
validated. The assay was validated by determination of sensitivity, linearity, accuracy, 
precision, and reproducibility by testing assay sensitivity, dilutional parallelism, spiking 
recovery, intra-assay variability, and inter-assay variability and by establishing a 
reference interval and assessing analyte stability.  
 
MATERIALS AND METHODS 
Materials - All commonly used research materials were purchased from VWR 
Scientific, West Chester, PA. Radiolabeled I125CCK-8 was purchased from Perkin 
Elmer, Waltham, MA (NEX203010UC) in 10 µCi amounts and used until its one-month 
expiration date. Synthetic sulfated CCK-8 used for making standards was purchased 
from Sigma-Aldrich, St. Louis, MO (C2175) and immediately reconstituted, diluted to a 
2.18 nM stock solution, aliquoted, and stored at -20°C. Antibody 92128-5 was obtained 
by generous donation from the lab of Jens Rehfeld, Copenhagen, Denmark. Activated 
charcoal used in the separation solution was purchased from Sigma-Aldrich, St. Louis, 
MO (C7606) and stored at room temperature until use. Thimerosal, used in Barbital 
Buffer I, was purchased from Sigma-Aldrich, St. Louis, MO (T4687) and stored at room 
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temperature until use. Sodium azide, used in Barbital Buffer II, was purchased from 
Sigma-Aldrich, St. Louis, MO (S8032) and stored at room temperature until use. 
Barbital for use in the RIA buffers was purchased from Sigma-Aldrich, St. Louis, MO 
(B0375) via usage certification from the Large Animal Pharmacy at the College of 
Veterinary Medicine and Biomedical Sciences at Texas A&M University. Canine fresh 
frozen plasma was purchased from Animal Blood Resources International, Dixon, CA, 
or obtained from outdated bags within the laboratory or the Veterinary Medical 
Teaching Hospital at Texas A&M University. Newborn calf serum was purchased from 
Sigma-Aldrich, St. Louis, MO (N4637). The gamma counter used (1470 Wallac Wizard) 
was purchased from Perkin Elmer, Waltham, MA. Polypropylene RIA tubes were 
purchased from VWR Scientific, West Chester, PA. 
Adapted Protocol - After multiple assay runs as discussed in Chapter II, the 
final protocol, having been established, was used to validate the CCK radioimmunoassay 
for use in dogs. The adapted protocol used for validation is outlined as follows: One mL 
of NCS was thawed and diluted 1:20 with deionized water to create a 5% NCS solution. 
Four hundred µL aliquots of 5% NCS were dispensed into 2 mL sample tubes. Eight 
hundred µL of 96% (vol/vol) ethanol was then pipetted into each 400 µL NCS aliquot. 
The aliquots were then intermittently vortexed for 10 seconds each. After vortexing, the 
tubes were centrifuged for 15 minutes at 4,000 rpm at room temperature. The resulting 
clear supernatant was decanted from each tube into a fresh sample tube. The 
supernatants were evaporated at room temperature in a vacuum concentrator for 5 hours. 
These extracts were then reconstituted to their original 400 µL volume with standards or 
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controls for the assay run, or stored at -20°C until use. Canine samples were obtained 
through external jugular venipuncture and placed in either red whole blood tubes or 
serum separator tubes and centrifuged for 18 minutes at 3,500 rpm. Serum was pipetted 
from the remaining blood components and 400 µL aliquots were placed into 2 mL 
sample tubes. Eight hundred µL of 96% (vol/vol) ethanol was then pipetted into each 
400 µL sample aliquot. The aliquots were then intermittently vortexed for 10 seconds 
each. After vortexing, the tubes were centrifuged for 15 minutes at 4,000 rpm at room 
temperature. The resulting clear supernatant was decanted from each tube into a fresh 
sample tube. The supernatants were evaporated at room temperature in a vacuum 
concentrator for 5 hours. After drying, another 800 µL of 96% (vol/vol) ethanol was 
pipetted into each dried sample aliquot. The solution was evaporated at room 
temperature in a vacuum concentrator for another 5 hours. The sample extracts were 
then reconstituted to their original 400 µL volume with barbital buffer I (20 mM barbital, 
0.6 mM thimerosal, 0.11 % NCS, pH 8.4) for the assay run, or stored at -20°C until use.  
Barbital buffer II contained 20 mM barbital and 0.13 g/L sodium azide, also pH 8.4. 
After achieving proper pH, both buffers were filtered through a 0.2 µm filter and 
degassed. Standards were made using commercially available synthetic sulfated CCK-8. 
Two hundred-fifty µg of CCK-8 was reconstituted in 10 mL of barbital buffer I. The 
resulting 2.19 x 10-5 M solution was diluted to 2.19 x 10-10 M using barbital buffer I to 
create a working solution. One, 2.5, 5, 10, 20, 30, and 50 pM standards were prepared 
from the standard working solution. Four, 7.5, and 15 pM controls were also prepared 
from the standard working solution. Each standard was raised to the desired volume 
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using barbital buffer I as the diluent. To carry out the assay, RIA tubes were used in 
duplicate, with tubes for total count (TC), non-specific binding (NSB), total binding 
(TB), and each standard or control. On the day of the assay, the antibody, albumin 
extracts, standards, and controls were taken out of the freezer and thawed at room 
temperature. Barbital buffer I was taken out of the refrigerator and allowed warm to 
room temperature. RIA tubes were arranged and labeled in duplicate fashion. Tracer was 
taken out of the freezer in the GI Lab radiation room and then diluted with barbital 
buffer I to 1,000 cpm +/- 100 cpm based on gammacounter readings for 60 seconds. 
Barbital buffer I was placed in each tube in the respective amounts as described in 
Figure 1. Newborn calf serum extract tubes were reconstituted to 400 µL with standard 
and controls, and then added to each tube in an amount as described in Figure 1. Sample 
extract tubes were reconstituted to 400 µL with barbital buffer I and added to each tube 
in an amount as described in Figure 1. Antibody 92128-5 was diluted to a dilution of 
1:20,000 using barbital buffer I and added to each tube in an amount as described in 
Figure 1. All tubes were then taken to a separate radiation room where 100 µL of tracer 
were added to each tube. All tubes were vortexed and allowed to incubate for 3 days at 
4°C. On day 3, a separation solution was prepared using 80 mL barbital buffer II, 20 mL 
canine plasma, and 6 g of activated charcoal. The solution was kept on ice and 
vigorously mixed on a magnetic stirrer for 30 minutes. After 30 minutes, 500 µL of 
separation solution was added to each tube. All tubes were vortexed and allowed to 
incubate at room temperature for 25 minutes. All tubes were then centrifuged for 10 
minutes at 4,000 rpm at 4°C. The supernatant from all tubes (except TC tubes) was 
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transferred from the original tube to a new tube, tapping once. The supernatant tubes 
were counted in an automatic gammacounter for 5 minutes and results were expressed as 
counts per minute. The cpm data was entered into an Excel® spreadsheet where average, 
standard deviation, correlation of variance, and B/B0 were calculated. B/B0 was 
calculated using the formula: B/B0 = (B - NSB) / (B0 - NSB), where NSB is the non-
specific binding cpm, B is the supernatant cpm, and B0 is the total binding (TB) cpm. A 
four-parameter log-logistic (4PL) standard curve was generated in Prism 6® by plotting 
the logarithm of the concentration against B/B0. All unknown values were extrapolated 
based on where their B/B0 falls along the standard curve. 
Validation - Assay sensitivity was determined using 10 duplicates of the total 
binding tube. Each duplicate received 1,000 µL barbital buffer I, 150 µL reconstituted 
NCS extract, 150 µL diluted antibody 92128-5, and 100 µL I125CCK-8 tracer. The 
modified canine RIA protocol was run with standards, and the resulting cpm data was 
evaluated by calculating the mean and standard deviation of the 10 duplicates. Three 
standard deviations were subtracted from the mean count and the value plotted on the 
standard curve to determine the corresponding CCK concentration. This calculated 
sensitivity was also used as the lower limit of the working range. To determine dilutional 
parallelism, spiking recovery, intra-assay variability, and inter-assay variability, 300 
leftover serum samples from dogs for which serum had been submitted for diagnostic 
testing to the Gastrointestinal Laboratory at Texas A&M University were evaluated 
using the new protocol to find samples with CCK concentrations that fell into different 
areas of the working range of the assay. For dilutional parallelism, 3 serum samples were 
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selected and tested at full strength, and at dilutions of 1 in 2, 1 in 4, and 1 in 8. For 
spiking recovery, 3 pools of serum were generated from the 300 serum samples to obtain 
sufficient serum volume to carry out the validation experiments. Serum pools were 
spiked with a known concentration of CCK-8 such that they would fall into different 
areas of the working range of the assay. Spiking recovery was determined by taking 
samples from the 3 serum pools and spiking them with 0, 1.25, 2.5, and 5 pM of CCK in 
barbital buffer I. For intra-assay variability and inter-assay variability, 4 pools of serum 
were generated from the 300 serum samples to obtain sufficient serum volumes to carry 
out the assay. Serum pools were spiked with a known concentration of CCK-8 such that 
they would fall into different areas of the working range of the assay. Intra-assay 
variability was determined by evaluating 4 different serum samples 6 times within the 
same assay run. Inter-assay variability was determined by evaluating 4 different serum 
samples in 6 consecutive assay runs. A reference interval for CCK in canine serum was 
established using 90 serum samples from clinically healthy, fasted (12 hrs) dogs using 
the lower 97.5th percentile. A stability study was conducted to determine the stability of 
CCK in canine serum under different storage conditions. Nine canine serum samples 
were obtained from healthy, fasted dogs (12 hrs). The samples were aliquoted into 5 
different 2 mL sample tubes using a volume of 400 µL each. An aliquot from each dog 
was measured for CCK at the following time points: immediately (baseline); after 24 
hours at 4°C or -80°C; after 1 week at -80°C; and after 4 weeks at -80°C. Prism 6® was 
used for all analyses. Each data set was tested for normality by use of a Kolmogoro-
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Smirnov normality test. For stability evaluation, serum CCK concentrations were 
compared by use of repeated-measures ANOVA with multiple comparisons.   
 
RESULTS 
 A typical standard curve for the assay is shown in Figure 4. The sensitivity of the 
assay was calculated to be 0.5 pM using three standard deviations from the mean of 10 
assay runs of a sample containing no CCK (Table 10). Thus, the lower limit of the 
working range of the assay was also 0.5 pM. For dilutional parallelism, observed-to-
expected ratios ranged from 101.9 % to 253.6 % (162.4 % ± 54.4 %) for 3 different 
canine serum samples at dilutions of 1 in 2, 1 in 4, and 1 in 8 (Table 11). For spiking 
recovery, observed-to-expected ratios ranged from 81.4 % to 68.2 % (73.2 % ± 4.0 %) 
for 3 different canine serum samples at 4 different spiking concentrations (Table 12). 
Coefficients of variation for intra-assay variability of 4 pooled serum samples were 3.8, 
13.5, 7.9, and 3.9 % (Table 13). Coefficients of variation for inter-assay variability of 4 
pooled serum samples were 12.3, 11.6, 7.4, and 6.4 % (Table 14). The reference interval 
for serum CCK concentration was established as ≤ 2.8 pM (Fig 5). The serum 
concentrations for each of the 9 serum samples did not vary significantly in samples 







Table 10 – Sensitivity of CCK RIA. This table shows the results for the determination of 
the sensitivity of the assay using 10 duplicates of the total binding (TB) tube. The mean 
minus 3 standard deviations was plotted on a standard curve to obtain the sensitivity. 




Tube%ID% Tube%1% Tube%2% Mean%
%% cpm% cpm% cpm%
TB%1% 433.0% 428.9% 431.0%
TB%2% 428.1% 453.2% 440.7%
TB%3% 427.7% 425.1% 426.4%
TB%4% 423.2% 442.1% 432.7%
TB%5% 422.0% 437.8% 429.9%
TB%6% 431.7% 441.8% 436.8%
TB%7% 428.1% 442.2% 435.2%
TB%8% 443.0% 429.8% 436.4%
TB%9% 445.0% 431.8% 438.4%


















Table 11 – Dilutional parallelism of CCK RIA. This table shows the data from serial 
dilutions of 3 serum samples throughout the working range of the assay. All 3 serum 




Sample%A% Observed% Expected% O/E%ratio%
Dilution% pm% pm% %%
1%in%1% 14.2% %% %%
1%in%2% 7.3% 7.1% 101.9%
1%in%4% 5.2% 3.6% 146.7%
1%in%8% 2.6% 1.8% 143.9%
% % % % % % %
Sample%B% Observed% Expected% O/E%ratio%
Dilution% pm% pm% %%
1%in%1% 3.9% %% %%
1%in%2% 2.8% 1.9% 146.5%
1%in%4% 1.4% 1.0% 140.3%
1%in%8% 1.1% 0.4% 247.8%
% % % % % % %
Sample%C% Observed% Expected% O/E%ratio%
Dilution% pm% pm% %%
1%in%1% 3.9% %% %%
1%in%2% 2.1% 1.9% 107.7%
1%in%4% 1.7% 1.0% 173.2%















Table 12 – Spiking recovery of CCK RIA. This table shows the data obtained from the 
spiking recovery performed on 3 different serum sample pools in the lower end of the 




Added% Observed% Expected% O/E%ratio%
pM% pM% pM% %%
0% 2.9% % %
1.25% 3.0% 4.1% 72.3%
2.5% 3.7% 5.4% 68.2%
5% 6.1% 7.9% 77.8%
% % % % % % %
Pool%B%
Added% Observed% Expected% O/E%ratio%
pM% pM% pM% %%
0% 1.6% % %
1.25% 2.1% 2.8% 72.9%
2.5% 3.3% 4.1% 81.4%
5% 4.7% 6.6% 70.7%
% % % % % % %
Pool%C%
Added% Observed% Expected% O/E%ratio%
pM% pM% pM% %%
0% 2.4% % %
1.25% 2.6% 3.7% 70.6%
2.5% 3.5% 4.9% 71.5%








Table 13 – Intra-assay variability of CCK RIA. This table shows the results obtained 
from the determination of intra-assay variability for CCK RIA using 4 different serum 
pools. (SD = standard deviation; %CV = coefficient of variation).  
 
 
% % % Pool%1% Pool%2% Pool%3% Pool%4%
Number%of%repeats% 6% 6% 6% 6%
Mean%(pM)% 2.2% 3.0% 10.6% 21.1%
SD%(pM)% 0.1% 0.4% 0.8% 0.8%






Table 14 – Inter-assay variability of CCK RIA. This table shows the results obtained 
from the determination of inter-assay variability for CCK RIA using 4 different serum 





% % % Pool%1% Pool%2% Pool%3% Pool%4%
Number%of%repeats% 6% 5% 6% 6%
Mean%(pM)% 2.1% 3.5% 10.2% 19.9%
SD%(pM)% 0.3% 0.4% 0.7% 1.3%






Figure 5 – Reference interval for CCK RIA. The mean serum concentration for CCK as 
measured in 90 clinically healthy dogs was 1.03 ± 0.83 pmol/L. The reference interval 
was determined by the bottom 97.5th percentile and was ≤ 2.8 pmol/L. Several serum 
samples from healthy dogs were included in this assay run. The mean CCK 














































































































































Table 15 – ANOVA of stability study. This table shows the results of an ANOVA for 




Number%of%families% 1% % %
Number%of%comparisons%
per%family% 4% % %
α%(alpha)% 0.05% % %
Dunnett's%multiple%
comparisons%test% Mean%Diff.% 95%%CI%of%diff.% Significant?%
Baseline%vs.%4oC%for%24%h% I0.21% I0.52%to%0.10% No%
Baseline%vs.%I80oC%for%24%h% 0.27% I0.28%to%0.82% No%
Baseline%vs.%I80oC%for%7%d% 0.03% I0.38%to%0.45% No%

















 A radioimmunoassay for the measurement of CCK in canine serum was 
successfully analytically validated. The observed-to-expected ratios for dilutional 
parallelism ranged from 101.9% to 253.6%. All 3 pools had adequate dilution ratios at 1 
in 2; however, all 3 pools went above 140% at the 1 in 4 and 1 in 8 dilutions. This 
suggests that the assay has limited linearity in the lower end of the working range. 
Inferences for the higher end of the working range cannot be determined from this data. 
The observed to expected ratios for spiking recovery ranged from 81.4% to 68.2%. 
While no specific criteria exist for acceptable values of spiking recovery, all samples 
measured had a low recovery rate (81% to 68%). However, spiking led to increased 
concentrations suggesting, that while some of the spiked material was lost to 
measurement the assay does indeed measure the analyte in question.  
Coefficients of variation for intra-assay variability of 4 pooled serum samples 
were 3.8, 13.5, 7.9, and 3.9%. All 4 pools had CVs below 15%, which suggests that the 
assay is sufficiently precise. Coefficients of variation for inter-assay variability of 4 
pooled serum samples were 12.3, 11.6, 7.4, and 6.4%. Pool 2 only had 5 repeats due to 
an error encountered during the assay. All 4 pools had CVs below 15%, which suggests 
that the assay is sufficiently reproducible. The reference interval for the assay was 
calculated to be ≤ 2.8 pM from the lower 97.5th percentile of serum CCK concentrations 
in 90 clinically healthy dogs.  
The results of the stability study indicate that CCK is stable in serum when stored 
for no more than 30 days at temperatures that samples are routinely exposed to during 
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shipping and storage until extraction. Stability was not evaluated for samples at room 
temperature, thus samples obtained for analysis should be shipped at a maximum of 4°C. 
There was some variation of results between the different time points, but the sample 
with the highest CCK concentration showed the lowest variability.  
The radioimmunoassay for CCK described here is sufficiently accurate, precise, 
and reproducible, but has limited linearity in the lower end of the working range. To our 
knowledge, this is the first validation of a CCK RIA specific for canine serum, and 
without human reagents. Target values for the purposes of assay validation were taken 
from previously validated radioimmunoassays, although no specific standards for 
validation have been established.10,19 The purpose of this project was to successfully 
modify a CCK RIA for use in humans for the measurement of canine serum CCK. 
Clinical studies are necessary to determine the clinical usefulness of measuring CCK 















Cholecystokinin is an important neuroendocrine peptide in the gastrointestinal 
tract, being the major stimulant for exocrine pancreatic secretion and gall bladder 
contraction. Current research focuses on CCK outside the gastrointestinal tract in 
humans. While there is a wealth of information on CCK and disorders associated with 
alterations in CCK release in humans, there is a distinct lack of information on similar 
disorders in dogs. This is likely due to the complexity of current CCK RIAs and the use 
of human reagents.  
Thus, the objectives of this study were to modify a radioimmunoassay used for 
the measurement of plasma CCK in humans for use in dogs, to perform said assay 
without human reagents, and to analytically validate this modified immunoassay for use 
with canine serum. To accomplish the objectives, assay runs were set up to replace all 
human reagents that are part of the original protocol, followed by analytical validation of 
the adapted assay using canine serum samples by determination of sensitivity, dilutional 
parallelism, spiking recovery, intra-assay variability, and inter-assay variability. All 
objectives outlined above were successfully met, analytically validating a 
radioimmunoassay for the measurement of cholecystokinin in canine serum. An assay 
now exists that has been analytically validated for canine serum and is free of human 
reagents, allowing for accurate measurements to be made from routinely drawn canine 
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serum samples. This will allow future studies to determine the role of altered CCK 
secretion in dogs with GI disease.  
The radioimmunoassay for CCK described here is sufficiently accurate, precise, 
and reproducible, but has limited linearity in the lower end of the working range. After 
evaluating 90 serum samples from clinically healthy dogs with the validated RIA, the 
reference interval was established as 0.0 to 2.8 pM. Further research is needed to 
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